REG - Aptamer Group PLC - Block listing Interim Review

AptamerAnnouncement

27/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240827:nRSa6445Ba&default-theme=true

RNS Number : 6445B  Aptamer Group PLC  27 August 2024

27 August 2024

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

 

Block Listing Interim Review

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders to
enable innovation in the life sciences industry, makes the following
notification pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for
Companies regarding its existing block admission:

 

 

 Name of Company                                                                 Aptamer Group plc
 Name of Scheme                                                                  The Aptamer Group EMI Share Option Scheme
 Period of Return (from/to)                                                      25 February 2024 to 24 August 2024
 Number and class of securities not issued at the start of the period under the  1,666,477 Ordinary Shares
 scheme
 Number of securities issued under the scheme during the period                  0
 Balance under the scheme of securities not yet issued at the end of the period  1,666,477 Ordinary Shares
 Number and class of securities originally admitted and the date of admission    2,063,200 Ordinary Shares on 25 February 2022
 Name of contact and telephone number                                            Andrew Rapson +44 (0) 1904 217 404

 

 

 

 

- ENDS -

 

For further information, please contact:

 

 Aptamer Group plc                                        +44 (0) 1904 217 404

 Dr Arron Tolley
 SPARK Advisory Partners Limited - Nominated Adviser      +44 (0) 20 3368 3550

 Andrew Emmott / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker           +44 (0) 20 3657 0050

 James Pope / Andrew Thacker

 

 

About Aptamer Group plc

 

Aptamer (http://www.aptamergroup.com/)  develops custom affinity binders
through its proprietary Optimer(®) platform to enable new approaches in
therapeutics, diagnostics, and research applications.  The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer
platform.

 

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative.  The global affinity ligand market is currently worth
over $170 billion.  Optimer binders are engineered to address many of the
issues found with alternative affinity molecules, such as antibodies, and
offer new, innovative solutions to bioprocessing, diagnostic and
pharmaceutical scientists.

 

Aptamer has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses.  Through the unique Optimer technology and processes, scientists
and collaborators can make faster, more informed decisions that support
discovery and development across the Life Sciences.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRXXLFLZVLZBBX